A Phase 1 interventional study of Dabigatran Etexilate and Rabeprazol sodium in Non-alcoholic Fatty Liver Disease, sponsored by Boehringer Ingelheim. Completed at 1 site in Japan. Open to male participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2019-01-16.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Non-alcoholic Fatty Liver Disease with a site in Japan — 5 open to participants now, 9 under way, 6 of them phase 3. Non-alcoholic Fatty Liver Disease · Japan.
Among the 38 studies in Non-alcoholic Fatty Liver Disease with a site in Japan, this one is the 35th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2017, is one of 4 in phase 1, and was the 6th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →5 of the 38 studies in Non-alcoholic Fatty Liver Disease with a site in Japan are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Japan, United States, Australia and 5 more countries
Ages 18–75
GlaxoSmithKline · Sites in Japan, United States, Australia and 6 more countries
Ages 18–75
Eli Lilly and Company · Sites in Japan, United States, Argentina and 31 more countries
Ages 18+
Akero Therapeutics, Inc · Sites in Japan, United States, Argentina and 20 more countries
Ages 18–80
Hoffmann-La Roche · Sites in Japan, United States, Argentina and 24 more countries
Ages 18–80
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 20 Years to 40 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 24 · Phase 3 8 · Phase 4 1
First in 2015; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 60 across 1,177 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 220 across the 37 interventional studies, 400 across the 1 observational. Of the 27 that completed or were terminated, 17 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 38 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 5 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Non-alcoholic Fatty Liver Disease with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06151964AstraZenecaA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | 2027-01-29 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies in Non-alcoholic Fatty Liver Disease with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to investigate the relative Bioavailability (BA) of tablet formulation of Dabigatran etexilate (DE) with and without co-administration of rabeprazole in healthy male subjects.
The secondary objective is the evaluation and comparison of several pharmacokinetic parameters between the treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dabigatran etexilate given without rabeprazole and then Dabigatran etexilate given without rabeprazole.
Drug: Dabigatran Etexilate · Drug: Rabeprazol sodium
Tablet, film coated
Also known as: MICARDIS, PRITOR, TELMISARTAN
Tablet
Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Total Dabigatran (AUC0-tz).
This endpoint calculates area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 to the time of last quantifiable time point.
Time frame: Samples were collected 1 hour Pre-dose and at 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00 36:00 and 48:00 hours post dose.
Maximum Concentration of Total Dabigatran in Plasma (Cmax).
This outcome is maximum measured concentration of the total dabigatran in plasma
Time frame: Samples were collected 1 hour Pre-dose and at 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00 36:00 and 48:00 hours post dose.
Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Free Dabigatran (AUC0-tz).
This endpoint calculates area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 to the time of last quantifiable time point.
Time frame: Samples were collected 1 hour Pre-dose and at 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00 36:00 and 48:00 hours post dose.
Maximum Concentration of Free Dabigatran in Plasma (Cmax).
This outcome is maximum measured concentration of the free dabigatran in plasma
Time frame: Samples were collected 1 hour Pre-dose and at 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00 36:00 and 48:00 hours post dose.
Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).
This endpoint calculates area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity
Time frame: Samples were collected 1 hour Pre-dose and at 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00 36:00 and 48:00 hours post dose.
Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).
This endpoint calculates area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity.
Time frame: Samples were collected 1 hour Pre-dose and at 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 12:00, 24:00 36:00 and 48:00 hours post dose.
This was open label, 2 period, fixed sequence (RT), single arm study in 36 healthy male Japanese subjects. All subjects were orally treated with single dose of 110 milligram (mg) dabigatran etexilate (DE) tablet formulation alone in period 1 and with 20 mg rabeprazole tablet in period 2 with 4 days of rabeprazole pre-medication.
| Milestone | Dabigatran Etexilate 110 mg With and Without Rabeprazole 20 mg |
|---|---|
| Started | 36 |
| Completed | 36 |
| Not completed | 0 |
| Milestone | Dabigatran Etexilate 110 mg With and Without Rabeprazole 20 mg |
|---|---|
| Started | 36 |
| Completed | 35 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
This endpoint calculates area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 to the time of last quantifiable time point.
| Nanogram*Hour/ millilitre (ng*h/mL) | Dabigatran Etexilate 110 mg (Reference) | Dabigatran Etexilate 110 mg + Rabeprazole 20 mg Tablet (Test) |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Total Dabigatran (AUC0-tz). | 667 ± 123 | 192 ± 109 |
This outcome is maximum measured concentration of the total dabigatran in plasma
| Nano gram per milliliter (ng/mL) | Dabigatran Etexilate 110 mg (Reference) | Dabigatran Etexilate 110 mg + Rabeprazole 20 mg Tablet (Test) |
|---|---|---|
| Maximum Concentration of Total Dabigatran in Plasma (Cmax). | 83.1 ± 118 | 21.8 ± 105 |
This endpoint calculates area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 to the time of last quantifiable time point.
| Nanogram*Hour/ millilitre (ng*h/mL) | Dabigatran Etexilate 110 mg (Reference) | Dabigatran Etexilate 110 mg + Rabeprazole 20 mg Tablet (Test) |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Free Dabigatran (AUC0-tz). | 588 ± 119 | 164 ± 110 |
This outcome is maximum measured concentration of the free dabigatran in plasma
| Nanogram per milliliter (ng/mL) | Dabigatran Etexilate 110 mg (Reference) | Dabigatran Etexilate 110 mg + Rabeprazole 20 mg Tablet (Test) |
|---|---|---|
| Maximum Concentration of Free Dabigatran in Plasma (Cmax). | 72.9 ± 114 | 20.0 ± 103 |
This endpoint calculates area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity
| Nanogram*Hour/ millilitre (ng*h/mL) | Dabigatran Etexilate 110 mg (Reference) | Dabigatran Etexilate 110 mg + Rabeprazole 20 mg Tablet (Test) |
|---|---|---|
| Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞). | 702 ± 110 | 214 ± 96.6 |
This endpoint calculates area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity.
| Nanogram*Hour/ millilitre (ng*h/mL) | Dabigatran Etexilate 110 mg (Reference) | Dabigatran Etexilate 110 mg + Rabeprazole 20 mg Tablet (Test) |
|---|---|---|
| Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞). | 618 ± 107 | 188 ± 93.4 |
Collected over From first drug administration until 3 days after the last drug administration. Up to 10 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran Etexilate 110 mg (Reference) | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Dabigatran Etexilate 110 mg + Rabeprazole 20 mg (Test) | 0/35 (0%) | 0/35 (0%) | 0/35 (0%) |
Treated set (TS) : All enrolled subjects provided with trial medication and documented to have taken at least 1 dose of trial medication were included in the TS.
| Age, Continuous(Years) | Total Subjects |
|---|---|
| Mean | 26.3 ± 4.7 |
| Sex: Female, Male(Participants) | Total Subjects |
|---|---|
| Female | 0 |
| Male | 36 |
| Ethnicity (NIH/OMB)(Participants) | Total Subjects |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 36 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Total Subjects |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 36 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2017 to primary completion in Jul 2017, 2 months.
Results were first posted in Jan 2019, 1 year 5 months after primary completion.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 2 months is below that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran
Non-alcoholic Fatty Liver Disease →